Author

Junxia Chen

Observed names: Chen, Junxia, J Chen, JUNXIA CHEN

Institution: Chongqing Medical University

Observed institutions: City Of Hope National Medical Center, Mayo Clinic, Baylor College of Medicine, Providence Portland Medical Center, Moffitt Cancer Center, Massachusetts General Hospital, Tennessee Oncology, Sidney Kimmel Comprehensive Cancer Center, Chongqing Medical University, Icahn School of Medicine at Mount Sinai

ORCID: 0000-0002-8531-7562

Observed ORCID: 0000-0002-8531-7562

OpenAlex ID: A5074502773

circACTN4 promotes breast cancer cell cycle progression and oncogenesis via c-MYC induced histone H4 acetylation

2025 · KEFAN LIU, XIAOSONG WANG, et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 1

Abstract SP012: Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine signaling inhibitors

2021 · JI Griffiths, J Chen, et al. · Cancer Research · 1

Correction: The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC

2026 · Xiaosong Wang, Lei Xing, et al. · Molecular Cancer

PILRA serves as a diagnostic and prognostic biomarker and modulates the tumor immune microenvironment and immunotherapy response in breast cancer

2026 · Bowen Shi, Yan Yang, et al. · Frontiers in Immunology

Abstract OT3-03-01: Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer

2019 · H Han, E Hamilton, et al. · Cancer Research

Works count: 23

Citation count: 20

H-index: 1

I10-index: 1